China cancer biomarkers market is growing at a CAGR of around 11.8% during the forecast period. China has a strong market for cancer biomarkers due to huge government investments in R&D and Life Science projects, prevalence of cancer and increasing adoption of personalized medicine. All these factors are contributing to the growth of China cancer biomarker market. Biomarker- targeted therapies approval in China is led by the development of various oncology biomarkers, such as EGFR, RAS, HER2, BRCA. There efficacy in the diagnosis of treatment of cancer has led the researchers and biopharmaceuticals to focus personalized medicine on biomarkers for cancer. In addition, the Government of China is investing heavily in life science research spurring the development and adoption of biomarkers for personalized medicine. The 13th Five-year Plan (2015-2020) by the Chinese government will further fuel the growth of the market as the plan focusses on the development of innovative medicines, with biomedicine being identified as a key priority.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/china-cancer-biomarker-market
In October 2017, a US based company called Gentris, working in the field of genomic biomarkers in clinical studies, signed a Memorandum of Understanding to form a biomarker collaboration with the Shanghai Institutes of Preventative Medicine. This partnership is done with the objective to discover new biomarkers. It will result in the development of translational research and epidemiological projects based on pharmacogenomics. In addition, it will provide clinical sample banking, which are services provided by the Gentris to the clients in the US for clinical trials and genomic biomarker programs. This is augmenting the growth of the china cancer biomarker market.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/china-cancer-biomarker-market
In 2015, there were nearly 4.3 million new cancer patients in China including 730,000 cases of lung cancer, which accounted for 36% of the total cases. Early diagnosis and risk assessment are essential for Lung cancer diagnosis. Many factors involved in those processes could serve as biomarkers for early diagnosis or early screening tools for lung cancer which has augmented the growth of lung cancer. In January 2018, China’s FDA approved Amoy Diagnostics’ SuperARMS EGFR mutation analysis test as a companion diagnostic for EGFR TKI-based non-small cell lung cancer drugs.
Market Segmentation
China Cancer Biomarker Market by Biomarker Type
- Genetic Biomarker
- Protein Biomarker
China Cancer Biomarkers Market by Cancer Type
- Lung Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Other
China Cancer Biomarkers Market by Applications
- Drug Discovery and Development
- Diagnosis
- Risk Assessment
- Prognostics
China Cancer Biomarker Market by Profiling Technology
- Omics Technology
- Immunoassays
- Cytogenetics
- Bioinformatics
Company Profiles
- Abbott Laboratories Inc.
- Astellas Pharma Inc.
- Becton, Dickson and Co.
- Bio-Rad Laboratories, Inc.
- Danaher Corp.
- Hoffmann-La Roche Ltd.
- Merck and Co., Inc.
- Novartis AG
- Pfizer Inc.
- QIAGEN GmbH
- Thermo Fisher Scientific Inc.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
